Ticagrelor (Brilinta)
Platelet aggregation inhibitor (P2Y12 receptor antagonist)
Ticagrelor (Brilinta)
Forms and strengths
Form: TabletStrength: 60 mg, 90 mg
References
Indication
- Ticagrelor, combined with low-dose aspirin, is used to reduce the risk of further heart attack, stroke, or cardiovascular death in patients who have had acute coronary syndrome.
- Ticagrelor, combined with low-dose aspirin, is used for long-term secondary prevention in patients with a history of heart attack at least one year earlier who remain at high risk.
- Ticagrelor, combined with low-dose aspirin, is used to reduce the risk of a first heart attack or stroke in patients with coronary artery disease, type 2 diabetes, and a history of a coronary artery procedure (percutaneous coronary intervention).
Pregnancy
- The safety of ticagrelor during pregnancy has not been established, since no clinical studies have been conducted in pregnant women.
- Women who can become pregnant should use appropriate contraception while taking ticagrelor.
Breastfeeding
- It is not known whether ticagrelor passes into human breast milk, though studies in rats have shown that ticagrelor and its active metabolites are excreted into milk.
- Breastfeeding is not recommended while taking ticagrelor.
Geriatrics
- No overall differences in safety or effectiveness were seen between older and younger patients in large clinical trials.
- No dose adjustment is required based on age alone.
Pediatrics
- The safety and effectiveness of ticagrelor in patients under 18 years of age have not been established, and Health Canada has not authorized a pediatric indication.
- In a study of children with sickle cell disease, ticagrelor did not reduce painful crisis episodes, and it should not be used for this condition.
Dosage & Administration
- For acute coronary syndrome, treatment starts with a single 180 mg loading dose, then continues at 90 mg twice daily.
- For long-term secondary prevention after a heart attack at least one year earlier, the dose is 60 mg twice daily, with no loading dose required.
- For coronary artery disease with type 2 diabetes and a history of percutaneous coronary intervention, the dose is 60 mg twice daily, with no loading dose required.
- Ticagrelor is always taken together with a daily low dose of aspirin (75 to 150 mg), unless aspirin is specifically not suitable.
- Doses of aspirin above 150 mg daily are not recommended with ticagrelor, since higher aspirin doses may reduce ticagrelor's relative benefit.
- No dose adjustment is required for kidney impairment or for older adults.
- Ticagrelor is not recommended in patients with moderate or severe liver impairment.
- Patients who cannot swallow tablets whole may have the tablet crushed and mixed with water, or given through a feeding tube.
- If a dose is missed, the next dose should be taken at its regularly scheduled time; the missed dose should not be doubled up.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is no known antidote to reverse the effects of ticagrelor, and it cannot be removed by dialysis.
- The main risk of overdose is a prolonged increased risk of bleeding due to excessive platelet inhibition.
- Ticagrelor has been well tolerated in single doses up to 900 mg, though at higher doses, stomach upset becomes the limiting effect.
- Other possible effects of overdose include shortness of breath and pauses in the heart's rhythm (ventricular pauses).
- If bleeding occurs after an overdose, appropriate supportive measures should be taken, and heart rhythm monitoring should be considered.
Common side effects
- Shortness of breath (dyspnea) may occur and is usually mild to moderate, often improving with continued treatment.
- Nosebleeds may occur.
- Bruising more easily may occur.
- Nausea or diarrhea may occur.
- Dizziness may occur.
- Headache may occur.
- Low-grade bleeding, such as after a minor cut or procedure, may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Ticagrelor increases the risk of bleeding, which can be serious or life-threatening, including bleeding inside the skull.
- Slow or irregular heartbeats (bradyarrhythmias), including heart block, have been reported, sometimes requiring temporary pacing.
- A rare but serious blood disorder called thrombotic thrombocytopenic purpura has been reported very rarely.
- Central sleep apnea, a breathing problem during sleep, has been reported.
- Uric acid levels can rise, which may trigger gout or, rarely, kidney problems related to uric acid buildup.
- Kidney function can be affected, with creatinine levels rising during treatment for reasons that are not fully understood.
- Stopping ticagrelor too early increases the risk of a heart attack or cardiovascular death related to the underlying heart disease.
- Seek urgent medical attention for signs of serious bleeding, such as vomiting blood, black or bloody stools, coughing up blood, or a severe headache with confusion or weakness.
Use with caution
- Use with caution in patients with a tendency to bleed, such as from recent trauma, recent surgery, a clotting disorder, or recent gastrointestinal bleeding.
- Use with caution in patients at increased risk of trauma or falls.
- Use with caution in patients taking warfarin or other blood thinners, since combined use increases bleeding risk.
- Use with caution in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs), which can add to bleeding risk.
- Use with caution in patients at risk for slow heart rhythms, including those with a history of bradyarrhythmia.
- Use with caution in patients with a history of gout or high uric acid levels.
- If elective surgery is planned and antiplatelet effect is not wanted, ticagrelor should be stopped about 5 days beforehand.
- Do not stop ticagrelor early without discussing it with your doctor, since premature discontinuation increases cardiovascular risk.
Contraindications
- Contraindicated in patients with known hypersensitivity to ticagrelor or any ingredient in the formulation.
- Contraindicated in patients with active pathological bleeding, such as a peptic ulcer.
- Contraindicated in patients with a history of bleeding inside the skull (intracranial hemorrhage).
- Contraindicated in patients with moderate to severe liver impairment.
- Contraindicated with strong CYP3A4 inhibitor drugs, such as ketoconazole, clarithromycin, and ritonavir, because they can greatly increase ticagrelor blood levels.
Drug interactions
- Strong CYP3A4 inhibitors, such as ketoconazole and clarithromycin, significantly raise ticagrelor blood levels and are contraindicated.
- Strong CYP3A4 inducers, such as rifampin, phenytoin, and carbamazepine, can significantly lower ticagrelor blood levels and reduce its effectiveness; alternative treatments should be considered.
- Simvastatin and lovastatin doses above 40 mg should be avoided with ticagrelor, since ticagrelor raises their blood levels and the risk of muscle toxicity.
- Rosuvastatin doses above 20 mg should be avoided with ticagrelor for the same reason.
- Digoxin blood levels can rise when combined with ticagrelor, so monitoring is recommended.
- Warfarin combined with ticagrelor increases bleeding risk, and the combination should be used with caution.
- Morphine and other opioids can delay and reduce the absorption of ticagrelor by slowing stomach emptying.
- Ticagrelor does not appear to reduce the effectiveness of hormonal contraceptives.
Food interactions
- Ticagrelor can be taken with or without food; a high-fat meal does not meaningfully change how much of the drug reaches the bloodstream.
Time of administration
- Ticagrelor is taken twice daily, approximately 12 hours apart, with or without food.
Storage
- Store ticagrelor tablets between 2°C and 30°C.
Patient take-away
- Ticagrelor is an antiplatelet medicine, always used together with low-dose aspirin, that helps prevent heart attack and stroke in people with heart disease.
- Take it exactly as prescribed and do not stop taking it early without talking to your doctor, since stopping suddenly raises your risk of a heart attack.
- This medicine increases your risk of bleeding, so tell every healthcare provider, including your dentist, that you are taking it.
- Report any unusual or severe bleeding, shortness of breath, or signs of an irregular or slow heartbeat right away.
- Avoid taking aspirin doses higher than what your doctor recommends while on this medicine.